Jaguar Health stockholders approve six proposals at November 2026 special meeting

Jaguar Health, Inc. (NASDAQ: JAGX) held a special meeting of stockholders on November 6, 2026, where the company held a special meeting of stockholders and six proposals were submitted to and approved by stockholders.¹

The approved items included a proposal to allow issuance of common stock upon exchange of Series Q Preferred Stock and CVP Debt tied to affiliates of Chicago Venture Partners, L.P., which was approved by a vote of 1,770,099 for to 133,740 against, with 10,170 abstentions and 1,469,160 broker non-votes.¹ Stockholders also approved repricing certain investor warrants to a new exercise price of $1.00 per share, entitling holders to additional shares from Series O and Series R Preferred Stock dividends.¹

A third proposal expanded the 2014 Stock Incentive Plan, increasing authorized shares to 378,859, representing 14% of outstanding common stock on a fully diluted basis as of September 30, 2026.¹

Stockholders also approved a reverse stock split amendment, authorizing a ratio between 1-for-2 and 1-for-150 at the board's discretion, to be announced within one year of approval, by a vote of 3,551,428 for to 222,394 against.¹ The filing notes a caveat on this item: "Proposal 4 was approved under the Votes Cast Standard, but not approved under the Majority of Outstanding Standard."¹

Stockholders further approved amending an existing stock purchase agreement with C/M Capital Master Fund, LP, reducing the floor price from $16.50 to $1.10 per share.¹ Finally, a proposal to allow adjournment of the meeting if needed to solicit additional proxies was approved by a vote of 3,386,070 for to 389,712 against.¹